Read More

Anavex Life Sciences Announces Late-Breaking Presentation Of Phase 2b/3 Data of Oral ANAVEX 2-73 (blarcamesine) For Early Alzheimer’s Disease At Upcoming Clinical Trials On Alzheimer’s Disease (CTAD) Congress 2022

Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and

AVXL

Read More

PerkinElmer Anticipated Organic Revenue Growth, Non-COVID Organic Revenue Growth And Adj. EPS For Q3 To Exceed Prior Guidance

The Company also announced that it anticipates organic revenue growth, non-COVID organic revenue growth, and adjusted earnings per share for the third quarter ended October 2, 2022 to exceed itsThe Company also announced that it anticipates organic revenue growth, non-COVID organic revenue growth, and adjusted earnings per share for the third quarter ended October 2, 2022 to

PKI